Literature DB >> 17956215

Pharmaceutical and biomedical potential of surface engineered dendrimers.

Jitendra Satija1, Umesh Gupta, Narendra Kumar Jain.   

Abstract

Dendrimers are hyperbranched, globular, monodisperse, nanometric polymeric architecture, having definite molecular weight, shape, and size (which make these an inimitable and optimum carrier molecule in pharmaceutical field). Dendritic architecture is having immense potential over the other carrier systems, particularly in the field of drug delivery because of their unique properties, such as structural uniformity, high purity, efficient membrane transport, high drug pay load, targeting potential, and good colloidal, biological, and shelf stability. Despite their enormous applicability in different areas, the inherent cytotoxicity, reticuloendothelial system (RES) uptake, drug leakage, immunogenicity, and hemolytic toxicity restricted their use in clinical applications, which is primarily associated with cationic charge present on the periphery due to amine groups. To overcome this toxic nature of dendrimers, some new types of nontoxic, biocompatible, and biodegradable dendrimers have been developed (e.g., polyester dendrimer, citric acid dendrimer, arginine dendrimer, carbohydrate dendrimers, etc.). The surface engineering of parent dendrimers is graceful and convenient strategy, which not only shields the positive charge to make this carrier more biomimetic but also improves the physicochemical and biological behavior of parent dendrimers. Thus, surface modification chemistry of parent dendrimers holds promise in pharmaceutical applications (such as solubilization, improved drug encapsulation, enhanced gene transfection, sustained and controlled drug release, intracellular targeting) and in the diagnostic field. Development of multifunctional dendrimer holds greater promise toward the biomedical applications because a number of targeting ligands determine specificity in the same manner as another type of group would secure stability in biological milieu and prolonged circulation, whereas others facilitate their transport through cell membranes. Therefore, as a consequence of ideal hyperbranched architecture and the biocompatible nature of engineered dendrimers, their utilization has been included in the scope of this review, which focuses on current surface alteration strategies of dendrimers for their potential use in drug delivery and explains the possible beneficial applications of these engineered dendrimers in the biomedical field.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956215     DOI: 10.1615/critrevtherdrugcarriersyst.v24.i3.20

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  10 in total

Review 1.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

2.  Zwitterionic chitosan derivatives for pH-sensitive stealth coating.

Authors:  Peisheng Xu; Gaurav Bajaj; Tyler Shugg; William G Van Alstine; Yoon Yeo
Journal:  Biomacromolecules       Date:  2010-09-13       Impact factor: 6.988

3.  Functionalized positive nanoparticles reduce mucin swelling and dispersion.

Authors:  Eric Y T Chen; Yung-Chen Wang; Chi-Shuo Chen; Wei-Chun Chin
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

Review 4.  Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.

Authors:  Mostafa Akbarzadeh Khiavi; Azam Safary; Jaleh Barar; Amir Ajoolabady; Mohammad Hossein Somi; Yadollah Omidi
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

5.  Studying complexes between PPI dendrimers and Mant-ATP.

Authors:  A Szulc; D Appelhans; B Voit; M Bryszewska; B Klajnert
Journal:  J Fluoresc       Date:  2013-01-11       Impact factor: 2.217

6.  Development of lipidoid-siRNA formulations for systemic delivery to the liver.

Authors:  Akin Akinc; Michael Goldberg; June Qin; J Robert Dorkin; Christina Gamba-Vitalo; Martin Maier; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Kallanthottathil G Rajeev; Muthiah Manoharan; Victor Koteliansky; Ingo Röhl; Elizaveta S Leshchiner; Robert Langer; Daniel G Anderson
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

7.  Estimation of tumor and local tissue dose in gold nanoparticles radiotherapy for prostate cancer.

Authors:  Amal Y Al-Yasiri; Nathan E White; Kattesh V Katti; Sudarshan K Loyalka
Journal:  Rep Pract Oncol Radiother       Date:  2019-04-09

8.  Different patterns of nuclear and mitochondrial penetration by the G3 PAMAM dendrimer and its biotin-pyridoxal bioconjugate BC-PAMAM in normal and cancer cells in vitro.

Authors:  Łukasz Uram; Magdalena Szuster; Aleksandra Filipowicz; Krzysztof Gargasz; Stanisław Wołowiec; Elżbieta Wałajtys-Rode
Journal:  Int J Nanomedicine       Date:  2015-09-04

9.  Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted with Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells.

Authors:  Łukasz Uram; Aleksandra Filipowicz-Rachwał; Maria Misiorek; Aleksandra Winiarz; Elżbieta Wałajtys-Rode; Stanisław Wołowiec
Journal:  Biomolecules       Date:  2019-09-01

Review 10.  Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.

Authors:  Rudy Juliano; Md Rowshon Alam; Vidula Dixit; Hyumin Kang
Journal:  Nucleic Acids Res       Date:  2008-06-16       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.